Trametinib 0.5 mg

DRUG2 trials

Sponsors

GlaxoSmithKline, Memorial Sloan Kettering Cancer Center

Conditions

CancerKRAS Gene MutationNon Small Cell Lung Cancer

Phase 1

A Pharmacokinetics (PK) and Safety Study to Determine the Effect of Repeat Dosing of Trametinib on Combined Oral Contraceptive (Norethindrone Plus Ethinyl Estradiol) in Female Subjects With Solid Tumors

WithdrawnNCT02292732

GlaxoSmithKlineCancer

Start: 2016-02-29End: 2017-05-31Updated: 2016-01-26

Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer

CompletedNCT03704688

Memorial Sloan Kettering Cancer CenterKRAS Gene Mutation, Non Small Cell Lung Cancer

Start: 2018-10-09End: 2022-02-04Updated: 2025-05-16